ABSTRACT
The COVID-19 pandemic in Toronto, Canada was unequal for its 2.7 million residents. As a dynamic pandemic, COVID-19 trends might have also varied over space and time. We conducted a spatiotemporal hotspot analysis of COVID-19 over the first four major waves of COVID-19 using three different applications of Moran’s I to highlight the variable experience of COVID-19 infections in Toronto, while describing the potential impact of socioeconomic and sociodemographic factors on increased risk of COVID-19 exposure and infection. Results highlight potential clustering of COVID-19 case rate hot spots in areas with higher concentrations of immigrant and low-income residents and cold spots in areas with more affluent and non-immigrant residents during the first three waves. By the fourth wave, case rate clustering patterns were more dynamic. In all, a better understanding of the unequal COVID-19 pandemic experience in Toronto needs to also consider the dynamic nature of the pandemic.
HIGHLIGHTS
- The COVID-19 pandemic was spatially and temporarily dynamic in the City of Toronto.
- At first, hotspots were concentrated in areas with more marginalized residents.
- Later, COVID-19 spatial trends diverged from initially identified patterns.
- East Asian enclaves in the city disproportionally had lower COVID-19 case counts.
- COVID-19 studies need to consider the dynamic nature of the pandemic.
Competing Interest Statement
DNF has served on advisory boards related to influenza and SARS-CoV-2 vaccines for Seqirus, Pfizer, AstraZeneca, and Sanofi-Pasteur Vaccines, and has served as a legal expert on issues related to COVID-19 epidemiology for the Elementary Teachers Federation of Ontario and the Registered Nurses Association of Ontario. ART was employed by the Public Health Agency of Canada when the research was conducted. The work does not represent the views of the Public Health Agency of Canada. AA, MC, and EG have no competing interests to declare.
Funding Statement
AA is funded by the University of Toronto Data Science Institute Doctoral Fellowship as well as the Emerging & Pandemics Infections Consortium Doctoral Student Award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the University of Toronto Health Sciences Research Ethics Board (protocol number 44167).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data cannot be shared publicly due to data sharing agreements and legal restrictions. Census Data is publically available through Statistics Canada.
